Cost-effectiveness of a high-sensitivity cardiac troponin T systematic screening strategy compared with usual care to identify patients with peri-operative myocardial injury after major noncardiac surgery.
Journal
European journal of anaesthesiology
ISSN: 1365-2346
Titre abrégé: Eur J Anaesthesiol
Pays: England
ID NLM: 8411711
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
entrez:
1
2
2023
pubmed:
2
2
2023
medline:
3
2
2023
Statut:
ppublish
Résumé
About 300 million surgeries are performed worldwide annually and this figure is increasing constantly. Peri-operative myocardial injury (PMI), detected by cardiac troponin (cTn) elevation, is a common cardiac complication of noncardiac surgery, strongly associated with short- and long-term mortality. Without systematic peri-operative cTn screening, most cases of PMI may go undetected. However, little is known about cost effectiveness of a systematic PMI screening strategy with high-sensitivity cardiac troponin T (hs-cTnT) after noncardiac surgery. To assess, in patients with high cardiovascular risk, the cost-effectiveness of a systematic screening strategy using a hs-cTnT assay, to identify patients with PMI after major noncardiac surgery, compared with usual care. Cost-effectiveness analysis; single centre prospective cohort study. Spanish University Hospital. From July 2016 to March 2019, we included 1477 consecutive surgical patients aged ≥65 or if <65, with documented history of cardiovascular disease or impaired renal function, who underwent major noncardiac surgery and required at least an overnight hospital stay. We excluded patients aged <65 years without cardiovascular disease, undergoing minor surgery, or with an expected <24 h hospital stays. We conducted a decision-tree analysis, comparing a systematic screening strategy measuring hs-cTnT before surgery, and at the 2nd and 3rd days after surgery vs. a usual care strategy. We considered a third-party payer perspective and the outcomes of both strategies in the short-term (30 days follow-up). Information about costs was expressed in Euros-2021. We calculated the incremental cost-effectiveness ratio (ICER) of the systematic hs-cTnT strategy, defined as the expected cost per any additional PMI detected, and explored the robustness of the model using deterministic and probabilistic sensitivity analysis. ICER of the systematic hs-cTnT screening strategy. The ICER was €425 per any additionally detected PMI. The deterministic sensitivity analysis showed that a 15% variation in costs, and a 1% variation in the predictive values, had a minor impact over the ICER, except in case of the negative predictive value of the systematic hs-cTnT screening strategy. Monte Carlo simulations (probabilistic sensitivity analysis) showed that systematic hs-cTnT screening would be cost-effective in 100% of cases with a 'willingness to pay' of €780. Our results suggest that systematic peri-operative PMI screening with hs-cTnT may be cost-effective in the short-term in patients undergoing major noncardiac surgery. Economic evaluations, with a long-term horizon, are still needed. Clinicaltrials.gov identifier: NCT03438448.
Sections du résumé
BACKGROUND
About 300 million surgeries are performed worldwide annually and this figure is increasing constantly. Peri-operative myocardial injury (PMI), detected by cardiac troponin (cTn) elevation, is a common cardiac complication of noncardiac surgery, strongly associated with short- and long-term mortality. Without systematic peri-operative cTn screening, most cases of PMI may go undetected. However, little is known about cost effectiveness of a systematic PMI screening strategy with high-sensitivity cardiac troponin T (hs-cTnT) after noncardiac surgery.
OBJECTIVE
To assess, in patients with high cardiovascular risk, the cost-effectiveness of a systematic screening strategy using a hs-cTnT assay, to identify patients with PMI after major noncardiac surgery, compared with usual care.
DESIGN
Cost-effectiveness analysis; single centre prospective cohort study.
SETTING
Spanish University Hospital.
PATIENTS
From July 2016 to March 2019, we included 1477 consecutive surgical patients aged ≥65 or if <65, with documented history of cardiovascular disease or impaired renal function, who underwent major noncardiac surgery and required at least an overnight hospital stay. We excluded patients aged <65 years without cardiovascular disease, undergoing minor surgery, or with an expected <24 h hospital stays.
INTERVENTIONS
We conducted a decision-tree analysis, comparing a systematic screening strategy measuring hs-cTnT before surgery, and at the 2nd and 3rd days after surgery vs. a usual care strategy. We considered a third-party payer perspective and the outcomes of both strategies in the short-term (30 days follow-up). Information about costs was expressed in Euros-2021. We calculated the incremental cost-effectiveness ratio (ICER) of the systematic hs-cTnT strategy, defined as the expected cost per any additional PMI detected, and explored the robustness of the model using deterministic and probabilistic sensitivity analysis.
MAIN OUTCOME MEASURES
ICER of the systematic hs-cTnT screening strategy.
RESULTS
The ICER was €425 per any additionally detected PMI. The deterministic sensitivity analysis showed that a 15% variation in costs, and a 1% variation in the predictive values, had a minor impact over the ICER, except in case of the negative predictive value of the systematic hs-cTnT screening strategy. Monte Carlo simulations (probabilistic sensitivity analysis) showed that systematic hs-cTnT screening would be cost-effective in 100% of cases with a 'willingness to pay' of €780.
CONCLUSIONS
Our results suggest that systematic peri-operative PMI screening with hs-cTnT may be cost-effective in the short-term in patients undergoing major noncardiac surgery. Economic evaluations, with a long-term horizon, are still needed.
TRIAL REGISTRATION
Clinicaltrials.gov identifier: NCT03438448.
Identifiants
pubmed: 36722187
doi: 10.1097/EJA.0000000000001793
pii: 00003643-202303000-00005
doi:
Substances chimiques
Troponin T
0
Banques de données
ClinicalTrials.gov
['NCT03438448']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
179-189Commentaires et corrections
Type : ErratumIn
Type : CommentIn
Informations de copyright
Copyright © 2023 European Society of Anaesthesiology and Intensive Care. Unauthorized reproduction of this article is prohibited.
Références
Nepogodiev D, Martin J, Biccard B, et al. Global burden of postoperative death. Lancet 2019; 393:401.
Devereaux PJ, Chan MT, Alonso-Coello P, et al. Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2012; 307:2295–2304.
Spence J, LeManach Y, Chan M TV, Wang CY, et al. Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators. Association between complications and death within 30 days after noncardiac surgery. CMAJ 2019; 191:E830–E837.
vanWaes JA, Nathoe HM, de Graaff JC, et al. on behalf of the CHASE investigators. Myocardial injury after noncardiac surgery and its association with short-term mortality. Circulation 2013; 127:2264–2271.
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing noncardiac surgery: developed by the task force for cardiovascular assessment and management of patients undergoing noncardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC). Eur Heart J, 2022;ehac270. Available at: https://doi.org/10.1093/eurheartj/ehac270 .
Puelacher C, Bollen Pinto B, Mills NL, et al. Expert consensus on peri-operative myocardial injury screening in noncardiac surgery: a literature review. Eur J Anaesthesiol 2021; 38:600–608.
Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361:858–867.
Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on noncardiac surgery: cardiovascular assessment and management: the Joint Task Force on noncardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014; 35:2383–2431.
Duceppe E, Parlow J, MacDonald P, et al. Canadian Cardiovascular Society Guidelines on peri-operative cardiac risk assessment and management for patients who undergo noncardiac surgery. Can J Cardiol 2017; 33:17–32.
De Hert S, Staender S, Fritsch G, et al. Preoperative evaluation of adults undergoing elective noncardiac surgery: updated guideline from the European Society of Anaesthesiology. Eur J Anaesthesiol 2018; 35:407–465.
Botto F, Alonso-Coello P, Chan MT, et al. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology 2014; 120:564–578.
Mantha S, Foss J, Ellis JE, et al. Intense cardiac troponin surveillance for longterm benefits is cost-effective in patients undergoing open abdominal aorticsurgery: a decision analysis model. Anesth Analg 2007; 105:1346–1356.
Torborg A, Ryan L, Kantor G, et al. The pharmacoeconomics of routine postoperative troponin surveillance to prevent and treat myocardial infarction after noncardiac surgery. S Afr Med J 2014; 104:619–623.
Lurati Buse G, Manns B, Lamy A, Guyatt G, et al. Troponin T monitoring to detect myocardial injury after noncardiac surgery: a cost-consequence analysis. Can J Surg 2018; 61:185–194.
Popova E, Paniagua Iglesias P, Alvarez Garcia J, et al. Rationale and design of peri-operative myocardial ischemia: a protocol for troponin monitoring, prognostic thresholds, economic analysis and further insights into pathophysiology for noncardiac surgery patients. F1000Research 2019; 8:850.
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019; 40:237–269.
Alcock RF, Kouzios D, Naoum C, et al. Peri-operative myocardial necrosis in patients at high cardiovascular risk undergoing elective noncardiac surgery. Heart 2012; 98:792–798.
TreeAge Pro 2021, R1. TreeAge Software, Williamstown, MA; software available at http://www.treeage.com .
Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford University Press; 2006. ISBN: 978-0-19-8526629.
Normann J, Mueller M, Biener M, et al. Effect of older age on diagnostic and prognostic performance of high-sensitivity troponin T in patients presenting to an emergency department. Am Heart J 2012; 164:698–705. e4.
Mueller-Hennessen M, Giannitsis E. Do we need to consider age and gender for accurate diagnosis of myocardial infarction? Diagnosis (Berl) 2016; 3:175–181.
Puelacher C, Lurati Buse G, Seeberger D, et al. Peri-operative myocardial injury after noncardiac surgery: incidence, mortality, and characterization. Circulation 2018; 137:1221–1232.
Nagele P, Brown F, Gage BF, et al. High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. Am Heart J 2013; 166:325–332. e32.
Devereaux PJ, Xavier D, Pogue J, et al. POISE (Peri-operative ISchemic Evaluation) Investigators. Characteristics and short-term prognosis of peri-operative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med 2011; 154:523–528.
Berwanger O, Le Manach Y, Suzumura EA, et al. Association between preoperative statin use and major cardiovascular complications among patients undergoing noncardiac surgery: the VISION study. Eur Heart J 2016; 37:177–185.
Antoniou GA, Hajibandeh S, hahab Hajibandeh S, et al. Meta-analysis of the effects of statins on peri-operative outcomes in vascular and endovascular surgery. J Vasc Surg 2015; 61:519–532. e1.
Devereaux PJ, Mrkobrada M, Sessler DI, et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014; 370:1494–1503.
Devereaux PJ, Duceppe E, Guyatt G, et al. Dabigatran in patients with myocardial injury after noncardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet 2018; 391:2325–2334.